Fig. 3

ILEI KD does not influence proliferation and sensitivity towards c-MET-inhibiton-induced arrest in FAM3C-MET-amplified cancer cells. a Western blot analysis of ILEI secretion into conditioned media (CM) and expression in the five selected cell lines (parental) and their non-targeting (shCont) and ILEI (sh261 and sh506) shRNA KD derivatives. The two independent ILEI KD lines sh261 and sh506 are named based on the starting position of the shRNA targeting site in the ILEI mRNA. b Proliferation behavior of the five tumor cell lines in the presence of increasing concentrations of crizotinib determined by thymidine incorporation assay. Error bars represent SEM of three independent replicates. c in vitro proliferation capacity of the five selected human tumor cell lines and their control and ILEI shRNA KD derivatives after 24 h vehicle or crizotinib (500 nM) treatment determined by MTT assay. Each cell line is normalized to its own parental vehicle-treated control. Error bars represent SEM of three to six independent assays. Statistical significance was determined by one-way ANOVA and marked with asterisks (*p < 0.05; **p < 0.01; ***p < 0.001)